PTC/SB/08x (06-03 )
Approved for use through 07/31/2006 OMB 0651-0031
U.S. Patient and Trademark Office; U.S. DEPARTMENT OF COMMERCE
It is a collection of information unless it contains a valid OMB control number.

Remove Pages, Columns, Lines where

U.S. Pilitet and Trademak Office; U.S. DiSPARTINENT OF COMMEN

Under the Paperwork Reduction Act of 1995, no persons are required to respond to accelerate of information unfers of contains a valid CMS control number

Application Number

	, фриодоон ганион		
	Filing Date		
	First Named Inventor	Axel	FEGER
STATEMENT BY APPLICANT  Not for submission under 37 CFR 1.99)	Art Unit		
not for outsinosion under or or it many	Examiner Name		
	Attorney Docket Numb	er	ARY0003

U.S.PATENTS

Initial*	Cite No	Patent Number	Kind Code <sup>1</sup>	Issue Date	Name of Patentee or Applicant Re			Relevant Passages or Relevant Figures Appear		
	1	5335945		1994-08-09	Meyers					
	2	6155610		2000-12-05	Godeau et al.					
	3	6267415		2001-07-31	Frank					
If you wis	h to a	dd additional U.S. Pater	t citatio	n information p	lease click the	Add button.		Add		
			U.S.P	ATENT APPLI	CATION PUB	LICATIONS		Remove	•	
Examiner	Cite	Publication Number	Kind Code <sup>1</sup>	Publication	Name of Patentee or Applicant of cited Document		Relev	ant Passa	Lines wh	
Initial*	NO		Code.	Date	of cited Dock	ument	Figure	s Appear		
Initial*	1		Code	Date	of cited Doc.	ument	Figure	s Appear		
	1	dd additional U.S. Public							]	
	1	dd additional U.S. Publin	shed Ap		n information ;	please click the Ad				
	1 h to a		shed Ap	plication citatio	n information ;	please click the Ad	d buttor	Remove	blumns,Lir elevant or Relev	Ts

# Application Number Filing Date STATEMENT BY APPLICANT (Not for submission under 37 CFR 199) Application Number Filing Date First Numeer Inventor | Asel FEGER Art Unit | Examiner Name | Attorney Cooket Number | ARY10003

	2	4018	766	DE		1990-12-20	Norbert Meier		Ш
	3	1015	8114	DE		2003-06-26	Soren Schroeter		
	4	01/20	0216	wo		2010-03-22	Thomas Krebs		
If you wis	If you wish to add additional Foreign Patent Document citation information please click the Add button Add								
				NON-PATE	NT LITE	RATURE DO	CUMENTS	Remove	
Examiner Initials* Cite Include name of the author (in CAPITAL LETTERS), itse of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.							T5		
1									
If you wish to add additional non-patent literature document citation information please click the Add button Add									
EXAMINER SIGNATURE									
Examiner Signature Date Considered									

1 See Kinc Codes of USPTO Potent Documents at twex (JSPTO\_GOU) or MFEP 8016.4. Editor distin that issued the document, by the Nov-letter gold (WIPD Standard S13.). For Upspresse parties for comments, the noticed on the year of the register of the Emport or many precise or the serial under the Pathel document.

1 Kind of document by the appropriate symbols as andicated on the document under WIPO Standard S11.6 if possible. Applicant is to place a check mark here if Engine Insurages the seriation is attached.

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

# Application Number Filing Date STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99) Application Number Filing Date First Named Inventor Asset FEGER Art Unit Examiner Name Attorney Docket Number ARY10033

## CERTIFICATION STATEMENT

Please see 37	CFR 1.5	7 and	1.98 to make th	he appropriate	selection(s):
---------------	---------	-------	-----------------	----------------	---------------

That each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement. See 37 CFR 197(eV1).

## OR

That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquity, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 156(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 197(s)(c).

- See attached certification statement.
- Fee set forth in 37 CFR 1.17 (p) has been submitted herewith.
  - □ None

### SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

Signature	/anthony niewyk/	Date (YYYY-MM-DD)	2006-06-08
Name/Print	Anthony Niewyk	Registration Number	24871

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is for life and by the USPTO to process) an application. Confidentially is governed by \$5 U.S. C.12 and 37 CFR 1.14. This collection is estimated to take 1 hour to complete, including gathering, preparing and submitting the completed application from the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patient and Tradenar's Office, and Superinteed for Commence, P. 0. Bot 1450, Alexandria, V.32.11.450, DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, V.32.211.41.60

## Privacy Act Statement

The Privacy Act of 1974 (P.L. 93-579) requires that you be given certain information in connection with your submission of the attached form related to a patient application or patient. Accordingly, pursuant to the requirements of the Act, please be advised that. (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) famishing of the information solicided is voluntary, and (3) the principal purpose for which the information is used by the U.S. Patient and Trademan Kolfice is to process another examine your submission relation to a patient application or patient. If you do not furnish the requested process another examine your submission relation to the patient application or patient. If you do not furnish the requested the process another examines your submission, which may visually intermediate or for extension or about those when the basic high process another examines your submission, which may visually intermediate or for extension or a submission of the basic high process another examines your submission, which may

The information provided by you in this form will be subject to the following routine uses:

- The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these record s.
  - A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement neodiations.
  - A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record partains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
  - A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974. as amended, pusuant to 5 U.S.C. 552a(m).
  - A record related to an International Application filed under the Patent Cooperation Treaty in this system of records
    may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant
    to the Patent Cooperation Treaty.
  - A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
- 7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or hisher designe, cuting an inspection of records concluded by GSAs a part of that apency's responsibility to recommend improvements in records management practices and programs, under suthority of 4d U.S.C. 2004 and 2006. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
- A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S. C. 122(b) or issuance of a patent pursuant to 35 U.S. C. 151. Further, a record may be disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record via set float in an application which became abandomed or in which the proceedings were terminated and which application is referenced by either a published application, an application open to public inspections or an issuand patent.
  - A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.